Bks Advisors, Llc Buys Ciena Corp, SPDR Portfolio Developed World ex-US, CSX Corp, Sells …

Bks Advisors, Llc Buys Ciena Corp, SPDR Portfolio Developed World ex-US, CSX Corp, Sells Broadcom Inc, Alphabet Inc, Exact Sciences Corp.

Investment company Bks Advisors, Llc buys Ciena Corp, SPDR Portfolio Developed World ex-US, CSX Corp, SPDR Index Shares Fund Portfolio Emerging Markets, Twilio Inc, SPDR Portfolio Short Term Corporate Bond, The Trade Desk Inc, NVIDIA Corp, Takeda Pharmaceutical Co, Western Midstream Partners LP, Workday Inc, Nike Inc, Tesla Inc, Berkshire Hathaway Inc, RH, Shopify Inc, Canopy Growth Corp, Centene Corp, Vanguard FTSE Developed Markets, Constellation Brands Inc, DexCom Inc, 3M Co, Baxter International Inc, Coca-Cola Co, Crane Co, Square Inc, Fifth Third Bancorp, Marathon Petroleum Corp, Union Pacific Corp, The Travelers Inc, Organovo Holdings Inc, sells Broadcom Inc, Alphabet Inc, Exact Sciences Corp, Shire PLC, GrubHub Inc, Universal Display Corp, Five Below Inc, Lululemon Athletica Inc, SPDR S&P Emerging Markets Dividend, Intel Corp, Western Midstream Partners LP, Boeing Co, First Trust VL Dividend, Ulta Beauty Inc, Vanguard Div Appreciation, iShares Global 100, Align Technology Inc, Fiat Chrysler Automobiles NV, Southern Co, Valero Energy Corp, Advanced Micro Devices Inc, BP PLC, PacWest Bancorp, Calix Inc, Texas Capital Bancshares Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Bks Advisors, Llc. As of 2019Q1, Bks Advisors, Llc owns 200 stocks with a total value of $232 million. These are the details of the buys and sells.

For the details of BKS ADVISORS, LLC’s stock buys and sells,go to https://www.gurufocus.com/guru/bks+advisors%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of BKS ADVISORS, LLC

  1. SPDR S&P 600 Small Cap Value ETF (based on S&P Sma (SLYV) – 128,358 shares, 3.34% of the total portfolio. Shares added by 11.29%
  2. Apple Inc (AAPL) – 38,272 shares, 3.14% of the total portfolio. Shares added by 10.39%
  3. SPDR Select Sector Fund – Technology (XLK) – 97,028 shares, 3.10% of the total portfolio. Shares reduced by 0.36%
  4. Visa Inc (V) – 39,330 shares, 2.65% of the total portfolio. Shares reduced by 6.19%
  5. ServiceNow Inc (NOW) – 24,006 shares, 2.55% of the total portfolio. Shares reduced by 6.96%

New Purchase: Ciena Corp (CIEN)

Bks Advisors, Llc initiated holding in Ciena Corp. The purchase prices were between $32.87 and $43.68, with an estimated average price of $38.77. The stock is now traded at around $38.73. The impact to a portfolio due to this purchase was 1.61%. The holding were 99,670 shares as of .

New Purchase: CSX Corp (CSX)

Bks Advisors, Llc initiated holding in CSX Corp. The purchase prices were between $60.98 and $74.82, with an estimated average price of $69.36. The stock is now traded at around $75.87. The impact to a portfolio due to this purchase was 0.44%. The holding were 13,625 shares as of .

New Purchase: The Trade Desk Inc (TTD)

Bks Advisors, Llc initiated holding in The Trade Desk Inc. The purchase prices were between $109.56 and $213.57, with an estimated average price of $162.61. The stock is now traded at around $207.00. The impact to a portfolio due to this purchase was 0.26%. The holding were 3,000 shares as of .

New Purchase: NVIDIA Corp (NVDA)

Bks Advisors, Llc initiated holding in NVIDIA Corp. The purchase prices were between $127.99 and $183.94, with an estimated average price of $154.95. The stock is now traded at around $187.67. The impact to a portfolio due to this purchase was 0.26%. The holding were 3,420 shares as of .

New Purchase: Takeda Pharmaceutical Co Ltd (TAK)

Bks Advisors, Llc initiated holding in Takeda Pharmaceutical Co Ltd. The purchase prices were between $16.7 and $21.52, with an estimated average price of $20.07. The stock is now traded at around $19.08. The impact to a portfolio due to this purchase was 0.18%. The holding were 20,993 shares as of .

New Purchase: Workday Inc (WDAY)

Bks Advisors, Llc initiated holding in Workday Inc. The purchase prices were between $154.02 and $197.93, with an estimated average price of $181.52. The stock is now traded at around $197.93. The impact to a portfolio due to this purchase was 0.17%. The holding were 2,050 shares as of .

Added: SPDR Portfolio Developed World ex-US (SPDW)

Bks Advisors, Llc added to a holding in SPDR Portfolio Developed World ex-US by 236.46%. The purchase prices were between $26.18 and $29.6, with an estimated average price of $28.45. The stock is now traded at around $30.02. The impact to a portfolio due to this purchase was 0.84%. The holding were 94,347 shares as of .

Added: SPDR Index Shares Fund Portfolio Emerging Markets (SPEM)

Bks Advisors, Llc added to a holding in SPDR Index Shares Fund Portfolio Emerging Markets by 209.83%. The purchase prices were between $32 and $36.28, with an estimated average price of $34.78. The stock is now traded at around $36.76. The impact to a portfolio due to this purchase was 0.32%. The holding were 30,540 shares as of .

Added: Twilio Inc (TWLO)

Bks Advisors, Llc added to a holding in Twilio Inc by 99.72%. The purchase prices were between $81.25 and $135.66, with an estimated average price of $112.06. The stock is now traded at around $129.71. The impact to a portfolio due to this purchase was 0.31%. The holding were 11,216 shares as of .

Added: SPDR Portfolio Short Term Corporate Bond (SPSB)

Bks Advisors, Llc added to a holding in SPDR Portfolio Short Term Corporate Bond by 78.10%. The purchase prices were between $30.12 and $30.57, with an estimated average price of $30.34. The stock is now traded at around $30.45. The impact to a portfolio due to this purchase was 0.29%. The holding were 49,484 shares as of .

Added: Tesla Inc (TSLA)

Bks Advisors, Llc added to a holding in Tesla Inc by 40.65%. The purchase prices were between $260.42 and $347.31, with an estimated average price of $301.74. The stock is now traded at around $273.23. The impact to a portfolio due to this purchase was 0.14%. The holding were 4,138 shares as of .

Added: Berkshire Hathaway Inc (BRK.A)

Bks Advisors, Llc added to a holding in Berkshire Hathaway Inc by 33.33%. The purchase prices were between $287000 and $313875, with an estimated average price of $302958. The stock is now traded at around $316420.00. The impact to a portfolio due to this purchase was 0.13%. The holding were 4 shares as of .

Sold Out: Broadcom Inc (AVGO)

Bks Advisors, Llc sold out a holding in Broadcom Inc. The sale prices were between $230.96 and $300.71, with an estimated average price of $270.85.

Sold Out: Exact Sciences Corp (EXAS)

Bks Advisors, Llc sold out a holding in Exact Sciences Corp. The sale prices were between $61.98 and $96.5, with an estimated average price of $84.73.

Sold Out: Shire PLC (SHPG)

Bks Advisors, Llc sold out a holding in Shire PLC. The sale prices were between $172.15 and $179.2, with an estimated average price of $176.08.

Sold Out: Five Below Inc (FIVE)

Bks Advisors, Llc sold out a holding in Five Below Inc. The sale prices were between $102.32 and $131.63, with an estimated average price of $120.95.

Sold Out: Lululemon Athletica Inc (LULU)

Bks Advisors, Llc sold out a holding in Lululemon Athletica Inc. The sale prices were between $121.61 and $167.54, with an estimated average price of $145.83.

Sold Out: Western Midstream Partners LP (WES)

Bks Advisors, Llc sold out a holding in Western Midstream Partners LP. The sale prices were between $42.23 and $51.27, with an estimated average price of $47.88.

Here is the complete portfolio of BKS ADVISORS, LLC. Also check out:

1. BKS ADVISORS, LLC’s Undervalued Stocks

2. BKS ADVISORS, LLC’s Top Growth Companies, and

3. BKS ADVISORS, LLC’s High Yield stocks

4. Stocks that BKS ADVISORS, LLC keeps buying

Related Posts:

  • No Related Posts

-$0.07 Earnings Per Share Expected for Organovo Holdings Inc (ONVO) This Quarter

Renaissance Technologies LLC increased its position in Organovo by 25.4% in the third quarter. Renaissance Technologies LLC now owns …

Organovo logoWall Street brokerages expect that Organovo Holdings Inc (NASDAQ:ONVO) will report ($0.07) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Organovo’s earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.06). Organovo also reported earnings per share of ($0.07) in the same quarter last year. The business is scheduled to announce its next earnings results on Thursday, May 30th.

On average, analysts expect that Organovo will report full-year earnings of ($0.25) per share for the current financial year, with EPS estimates ranging from ($0.27) to ($0.24). For the next financial year, analysts anticipate that the business will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.30) to ($0.21). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Organovo.

Organovo (NASDAQ:ONVO) last issued its earnings results on Thursday, February 7th. The medical research company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. The business had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.87 million. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%.

ONVO has been the topic of a number of research reports. Zacks Investment Research raised shares of Organovo from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Friday, November 16th. HC Wainwright started coverage on shares of Organovo in a research report on Thursday, December 13th. They set a “buy” rating and a $2.50 price objective for the company.

Shares of ONVO opened at $1.06 on Tuesday. The stock has a market cap of $123.08 million, a price-to-earnings ratio of -3.31 and a beta of 1.84. Organovo has a 12-month low of $0.90 and a 12-month high of $2.09.

Several institutional investors have recently made changes to their positions in ONVO. ARK Investment Management LLC lifted its position in Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock worth $20,644,000 after purchasing an additional 3,090,669 shares during the period. BlackRock Inc. raised its holdings in shares of Organovo by 1.5% in the third quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock valued at $8,129,000 after buying an additional 102,486 shares during the last quarter. Virtu Financial LLC acquired a new stake in Organovo in the third quarter worth about $138,000. Renaissance Technologies LLC increased its position in Organovo by 25.4% in the third quarter. Renaissance Technologies LLC now owns 1,561,000 shares of the medical research company’s stock worth $1,795,000 after purchasing an additional 316,400 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Organovo by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock worth $5,487,000 after buying an additional 52,073 shares during the period. Institutional investors and hedge funds own 35.35% of the company’s stock.

About Organovo

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

See Also: What is a put option?

Get a free copy of the Zacks research report on Organovo (ONVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Organovo Holdings Inc (ONVO) Shares Bought by Vanguard Group Inc

Vanguard Group Inc boosted its holdings in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the …

Organovo logoVanguard Group Inc boosted its holdings in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,771,558 shares of the medical research company’s stock after buying an additional 52,073 shares during the quarter. Vanguard Group Inc owned approximately 4.12% of Organovo worth $5,487,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in shares of Organovo by 20.8% during the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock worth $20,644,000 after purchasing an additional 3,090,669 shares in the last quarter. BlackRock Inc. grew its stake in Organovo by 14.8% during the 2nd quarter. BlackRock Inc. now owns 6,966,411 shares of the medical research company’s stock valued at $9,753,000 after acquiring an additional 897,113 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Organovo by 179.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,244,600 shares of the medical research company’s stock valued at $1,742,000 after purchasing an additional 798,800 shares during the last quarter. Virtu Financial LLC acquired a new position in Organovo in the 3rd quarter valued at about $138,000. Finally, Vanguard Group Inc. boosted its holdings in Organovo by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after purchasing an additional 52,073 shares during the last quarter. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently commented on ONVO. Zacks Investment Research upgraded shares of Organovo from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Saturday, February 2nd. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 target price on the stock.

NASDAQ:ONVO traded up $0.01 during trading hours on Tuesday, reaching $1.07. 2,548 shares of the company’s stock were exchanged, compared to its average volume of 565,607. Organovo Holdings Inc has a 1-year low of $0.90 and a 1-year high of $2.09. The stock has a market cap of $127.86 million, a P/E ratio of -3.38 and a beta of 1.84.

Organovo (NASDAQ:ONVO) last released its earnings results on Thursday, February 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%. The company had revenue of $0.78 million during the quarter, compared to analysts’ expectations of $0.87 million. Analysts anticipate that Organovo Holdings Inc will post -0.25 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Fairfield Current and is owned by of Fairfield Current. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.fairfieldcurrent.com/news/2019/02/19/organovo-holdings-inc-onvo-stake-raised-by-vanguard-group-inc.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Why is a lock-up period needed for an IPO?

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Organovo Holdings Inc (ONVO) Stake Raised by Vanguard Group Inc

Vanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most …

Organovo logoVanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,771,558 shares of the medical research company’s stock after acquiring an additional 52,073 shares during the quarter. Vanguard Group Inc owned about 4.12% of Organovo worth $5,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Organovo in the third quarter valued at $138,000. Renaissance Technologies LLC raised its stake in shares of Organovo by 179.2% in the second quarter. Renaissance Technologies LLC now owns 1,244,600 shares of the medical research company’s stock valued at $1,742,000 after acquiring an additional 798,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Organovo by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after acquiring an additional 52,073 shares during the period. BlackRock Inc. raised its stake in shares of Organovo by 14.8% in the second quarter. BlackRock Inc. now owns 6,966,411 shares of the medical research company’s stock valued at $9,753,000 after acquiring an additional 897,113 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after acquiring an additional 3,090,669 shares during the period. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ONVO traded up $0.01 during mid-day trading on Tuesday, reaching $1.01. The company had a trading volume of 11,445 shares, compared to its average volume of 560,614. The stock has a market cap of $119.49 million, a PE ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 52 week low of $0.90 and a 52 week high of $2.09.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.87 million. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%. Research analysts forecast that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

Several equities research analysts have recently weighed in on ONVO shares. Zacks Investment Research downgraded shares of Organovo from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They issued a “buy” rating and a $2.50 price target on the stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/02/12/organovo-holdings-inc-onvo-stake-raised-by-vanguard-group-inc.html.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Intrinsic Value

Want to see what other hedge funds are holding ONVO?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organovo Holdings Inc (NASDAQ:ONVO).

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)

Renaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to …

Organovo logoRenaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,561,000 shares of the medical research company’s stock after purchasing an additional 316,400 shares during the quarter. Renaissance Technologies LLC owned 1.35% of Organovo worth $1,795,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ONVO. ARK Investment Management LLC lifted its holdings in Organovo by 20.8% in the 3rd quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after purchasing an additional 3,090,669 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Organovo by 1.5% during the 3rd quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock worth $8,129,000 after acquiring an additional 102,486 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Organovo during the 3rd quarter worth $138,000. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on ONVO shares. Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. HC Wainwright started coverage on Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 price target on the stock.

NASDAQ ONVO opened at $1.00 on Tuesday. The stock has a market capitalization of $119.49 million, a price-to-earnings ratio of -3.13 and a beta of 1.84. Organovo Holdings Inc has a 1-year low of $0.90 and a 1-year high of $2.09.

Organovo (NASDAQ:ONVO) last released its earnings results on Thursday, February 7th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.78 million during the quarter, compared to the consensus estimate of $0.87 million. Organovo had a negative return on equity of 67.55% and a negative net margin of 770.79%. Equities research analysts anticipate that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)” was originally published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/02/12/renaissance-technologies-llc-boosts-stake-in-organovo-holdings-inc-onvo.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts